Mojica MF, Rossi M-A, Vila AJ, Bonomo RA. The urgent need for metallo-β-lactamase inhibitors: an unattended global threat. Lancet. 2022;22(1):e28–34.

Article  CAS  Google Scholar 

Arya R, Goldner BS, Shorr AF. Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challenges. Curr Opin Infect Dis. 2022;35(6):589–94.

Article  CAS  PubMed  Google Scholar 

Liu B, Trout REL, Chu GH, Mcgarry D, Jackson RW, Hamrick JC, et al. Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-β-lactamase inhibitor for carbapenem-resistant bacterial infections. J Med Chem. 2020;63(6):2789–801.

Article  CAS  PubMed  Google Scholar 

Lang PA, Parkova A, Leissing TM, Calvopiña K, Cain R, Krajnc A, et al. Bicyclic boronates as potent inhibitors of AmpC, the class C β-lactamase from Escherichia coli. Biomolecules. 2020;10(6):899.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lomovskaya O, Castanheira M, Lindley J, Rubio-Aparicio D, Nelson K, Tsivkovski R, et al. In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales. Antimicrob Agents Chemother. 2023;67(11):e00440-e523.

Article  PubMed  PubMed Central  Google Scholar 

Isler B, Harris P, Stewart AG, Paterson DL. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. J Antimicrob Chemother. 2021;76(3):550–60.

Article  CAS  PubMed  Google Scholar 

Bassetti M, Castaldo N, Fantin A, Giacobbe DR, Vena A. Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives. Curr Opin Infect Dis. 2023;36(6):615–22.

Article  CAS  PubMed  Google Scholar 

Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM, et al. In vitro activity of cefepime–taniborbactam and comparators against clinical isolates of Gram-negative bacilli from 2018 to 2020: results from the global evaluation of antimicrobial resistance via surveillance (GEARS) program. Antimicrob Agents Chemother. 2023;67(1):e01281-e1322.

Article  PubMed  Google Scholar 

Wise M, Hackel M, Sahm D. In vitro activity of cefepime–taniborbactam and comparators against genotypically characterized carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) from the United States, 2018–2021 [abstract no. 1527470 plus poster]. IDweek; 11–15 October 2023: Boston, MA.

Hamrick JC, Docquier J-D, Uehara T, Myers CL, Six DA, Chatwin CL, et al. VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine-and metallo-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2020;64(3):e01963-e2019.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karvouniaris M, Almyroudi MP, Abdul-Aziz MH, Blot S, Paramythiotou E, Tsigou E, et al. Novel antimicrobial agents for Gram-negative pathogens. Antibiotics. 2023;12(4):761.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Losito AR, Raffaelli F, Del Giacomo P, Tumbarello M. New drugs for the treatment of Pseudomonas aeruginosa infections with limited treatment options: a narrative review. Antibiotics. 2022;11(5):579.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mackow NA, Van Duin D. Reviewing novel treatment options for carbapenem-resistant Enterobacterales. Expert Rev Anti Infect Ther. 2024;22(3):71–85.

Article  CAS  PubMed  Google Scholar 

Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, et al. Cefepime–taniborbactam in complicated urinary tract infection. N Eng J Med. 2024;390(7):611–22.

Article  CAS  Google Scholar 

BusinessWire Press Release. Venatorx and Melinta provide update on status of US new drug application for cefepime–taniborbactam. 2024. https://venatorx.com/press-releases/venatorx-and-melinta-provide-update-on-status-of-u-s-new-drug-application-for-cefepime-taniborbactam/. Accessed 8 Apr 2024.

Al KO. Review on characterization, properties, and analytical methods of cefepime. Int J Anal Chem. 2022;2022:1–10.

Google Scholar 

Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, et al. β-Lactamases and β-lactamase inhibitors in the 21st century. J Mol Biol. 2019;431(18):3472–500.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Endimiani A, Perez F, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther. 2008;6(6):805–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krajnc A, Brem J, Hinchliffe P, Calvopiña K, Panduwawala TD, Lang PA, et al. Bicyclic boronate VNRX-5133 inhibits metallo- and serine-β-lactamases. J Med Chem. 2019;62(18):8544–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bush K, Bradford PA. β-lactams and β-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8): a025247.

Article  PubMed  PubMed Central  Google Scholar 

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, et al. Imipenem–relebactam and meropenem–vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs. 2018;78(1):65–98.

Article  CAS  PubMed  Google Scholar 

Drusin SI, Le Terrier C, Poirel L, Bonomo RA, Vila AJ, Moreno DM. Structural basis of metallo-β-lactamase resistance to taniborbactam. Antimicrob Agents Chemother. 2023. https://doi.org/10.1128/aac.01168-23.

Article  PubMed  PubMed Central  Google Scholar 

Roach EJ, Uehara T, Daigle DM, Six DA, Khursigara CM. The next-generation β-lactamase inhibitor taniborbactam restores the morphological effects of cefepime in KPC-producing Escherichia coli. Microbiol Spectr. 2021;9(2):e00918-e921.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020;64(10):e00397-e420.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ono D, Mojica MF, Bethel CR, Ishii Y, Drusin SI, Moreno DM, et al. Structural role of K224 in taniborbactam inhibition of NDM-1. Antimicrob Agents Chemother. 2024;68(2):e01332-e1423.

Article  PubMed  PubMed Central  Google Scholar 

Hernández-García M, García-Castillo M, Nieto-Torres M, Bou G, Ocampo-Sosa A, Pitart C, et al. Deciphering mechanisms affecting cefepime–taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain. Eur J Clin Microbiol Infect Dis. 2024;43(2):279–96.

Article  PubMed  Google Scholar 

Golden AR, Baxter MR, Karlowsky JA, Mataseje L, Mulvey MR, Walkty A, et al. Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19. JAC Antimicrob Resist. 2022;4(1):dlab197.

Article  PubMed  PubMed Central  Google Scholar 

Satapoomin N, Dulyayangkul P, Avison MB. Klebsiella pneumoniae mutants resistant to ceftazidime-avibactam plus aztreonam, imipenem-relebactam, meropenem-vaborbactam, and cefepime–taniborbactam. Antimicrob Agents Chemother. 2022;66(4):e02179-e2221.

Article  PubMed  PubMed Central  Google Scholar 

Hujer AM, Marshall SH, Mack AR, Hujer KM, Bakthavatchalam YD, Umarkar K, et al. Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam. MBio. 2023;14(6): e01118.

Article  PubMed  PubMed Central  Google Scholar 

Mushtaq S, Vickers A, Doumith M, Ellington MJ, Woodford N, Livermore DM. Activity of β -lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2021;76(1):160–70.

Article  CAS  PubMed  Google Scholar